Bayer scientists on Tuesday discussed a June draft report from regulators in four European Union countries that concluded the chemical meets the EU approval criteria for renewed registration. They also underscored the company's belief that the product offers benefits of effectiveness not available in its alternatives.
To view this article, please
login. If you are not a current subscriber, you may sign up for a trial or view other subscription options
here.
![Steve headshot 250x200[1]](http://www.agri-pulse.com/ext/resources/Headshots/Staff-Photos/thumb/Steve_Headshot_250x200[1].JPG?1738947158)